retatrutide triple agonist weight loss trial New Phase 3 data just dropped 👀 Eli Lilly's reported average approaching 30%, with some patients achieving results historically associated with bariatric surgery. A few important caveats Triple hormone receptor agonist retatrutide

Retatrutides side effect profile is similar to other GLP-1 based medications

Read the full breakdown in what the FDA's July 30 deadline means for compounded semaglutide

We highlight how multireceptor agonists and oral GLP-1based therapies may reshape the future landscape of obesity and type 2 diabetes treatment by offering more effective and better-tolerated options

The clinical trial reported percentage weight loss rather than absolute weight, so researchers should calculate expected absolute weight changes based on the starting weight of their research subjects when designing study endpoints

Just make sure your medication is properly stored, as compounded formulations may have different stability profiles

What is the mechanism of action of Retatrutide